We acknowledge Aboriginal and Torres Strait Islander peoples as the First Australians and Traditional Custodians of the lands where we live, learn and work.
AbbVie has written the next chapter in its epic quest to treat psychiatric disorders, agreeing to buy a psychedelic drug candidate from Gilgamesh Pharmaceuticals for up to $1.2 billion. Bloomberg ...
NORTH CHICAGO, Ill. and NEW YORK, Aug. 25, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals Inc. ("Gilgamesh") today announced a definitive agreement under which AbbVie will ...
AbbVie has signed a definitive agreement to acquire Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, for up to $1.2bn, including an upfront payment and development milestones.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback